Gorakhpur

This research aims to assess the safety and effectiveness of guselkumab treatment in Indian adults with psoriatic arthritis, a chronic autoimmune condition causing joint inflammation. The study focuses on participants who have not responded well to standard therapies, including conventional drugs and biologics. It is a Phase IV, open-label, multicenter study designed to evaluate this treatment in a real-world setting. Participants will receive guselkumab as a subcutaneous injection. The study includes careful screening for tuberculosis before starting treatment, requiring specific tests and chest X-rays to rule out active or latent TB. The treatment phase lasts up to 32 weeks, during which participants will be monitored for any adverse events or serious adverse events. During the study, participants will undergo physical exams, medical history reviews, vital signs checks, and ECGs to ensure medical stability. Women of childbearing potential will have pregnancy tests. Researchers will closely track safety by recording any adverse events over the 32-week period. The study aims to gather comprehensive data on how well guselkumab works and how safe it is for treating psoriatic arthritis in this population.